AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

AbCellera Biologics: Strategic Shift and Clinical Advancements Drive Buy Rating Mar 03, 2025, 03:35 PM AbCellera Biologics: Strategic Shift and Clinical Advancements Drive Buy Rating Bloom Burton analyst David Martin PhD has maintained their bullish stance on ABCL stock, giving a Buy rating today. David Martin PhD has given his Buy rating due to a combination of factors that highlight AbCellera Biologics’ potential for growth. Despite the company’s recent financial results showing revenues below expectations, the alignment of earnings per share with forecasts indicates stability in its financial performance. Additionally, the strategic transition from a platform-based model to a pipeline-focused approach is a significant factor in the positive outlook. The imminent entry of two major therapeutic monoclonal antibodies into clinical trials this year underscores the company’s innovative capabilities and potential to capture substantial market opportunities, reinforcing the Buy rating. Martin PhD covers the Healthcare sector, focusing on stocks such as Repare Therapeutics, Aurinia Pharmaceuticals, and ESSA Pharma. According to TipRanks, Martin PhD has an average return of 16.5% and a 46.63% success rate on recommended stocks. https://www.tipranks.com/news/ratings/abcellera-biologics-strategic-shift-and-clinical-advancements-drive-buy-rating?mod=mw_quote_news#google_vignette

Seit 2020 hat abcellera jedes Jahr rekorde gebrochen... Jahr für Jahr ein neues minus Ziel 😅

AbCellera Biologics (ABCL) Gets a Buy from Truist Financial TipRanks Auto-Generated Intelligence Newsdesk Mar 03, 2025, 01:47 PM In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbCellera Biologics (ABCL – Research Report), with a price target of $28.00. The company’s shares closed last Friday at $2.59. According to TipRanks, Devarakonda is a 3-star analyst with an average return of 1.5% and a 41.62% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Cytokinetics, and Pfizer. In addition to Truist Financial, AbCellera Biologics also received a Buy from Stifel Nicolaus’s Stephen Willey in a report issued on February 28. However, today, Benchmark Co. maintained a Hold rating on AbCellera Biologics (NASDAQ: ABCL). https://www.tipranks.com/news/blurbs/abcellera-biologics-abcl-gets-a-buy-from-truist-financial-2?mod=mw_quote_news

AbCellera Biologics: Strategic Partnerships and Pipeline Developments Drive Buy Rating TipRanks Auto-Generated Intelligence Newsdesk Mar 03, 2025, 07:58 AM Puneet Souda, an analyst from Leerink Partners, maintained the Buy rating on AbCellera Biologics (ABCL – Research Report). The associated price target is $7.00. Puneet Souda has given his Buy rating due to a combination of factors that highlight AbCellera Biologics as a promising investment. The company is leveraging its substantial liquidity of over $800 million to develop an internal pipeline and establish high-value strategic partnerships. The year 2025 is expected to be significant for AbCellera, with key developments such as the CTA filings for ABCL635 and ABCL575 and the opening of a GMP facility. Additionally, the company plans to disclose the indication for ABCL635, which targets a metabolic condition with a $2 billion total addressable market, and to present preclinical data for ABCL575. Moreover, AbCellera is focusing on difficult targets like GPCR and ion channels, which could differentiate its pipeline and attract strategic partners, especially in light of increasing competition. Although partner programs are no longer the main focus, three partner programs entered Phase I in the fourth quarter, potentially driving future milestone and royalty revenue. The stock is trading near its total liquidity, suggesting potential upside from its royalty portfolio and internal pipeline. These factors contribute to the optimistic outlook and the Buy rating for AbCellera Biologics. In another report released on February 28, Stifel Nicolaus also maintained a Buy rating on the stock with a $10.00 price target. https://www.tipranks.com/news/ratings/abcellera-biologics-strategic-partnerships-and-pipeline-developments-drive-buy-rating?mod=mw_quote_news

@Hopper58 danke fürs Teilen, habe heute nochmals zugegriffen. 🖖

Unter 2 Dollar

AbCellera price target lowered to $10 from $12 at Stifel TheFly Feb 28, 2025, 01:30 PM AbCellera price target lowered to $10 from $12 at Stifel Stifel lowered the firm’s price target on AbCellera (ABCL) to $10 from $12 and keeps a Buy rating on the shares. The firm believes FY25 “marks an important inflection point” as the company completes the transition from a discovery-focused partner to a fully-integrated drug development company, the analyst tells investors. The firm’s updated estimates mostly reflect reduced partnership-derived revenue and revised financing assumptions, the analyst noted.

https://www.gurufocus.com/news/2721808/abcellera-biologics-inc-abcl-q4-2024-earnings-call-highlights-strategic-shifts-amid-financial-challenges?r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news

Carl Hansen -- Chief Executive Officer 'So the partnering objective (AbbVie) was to make a significant transaction with a large and enabled partner that has a commitment to really put some time and money into that space. We have a previous collaboration with AbbVie. So we've got an excellent working relationship and have been productively working on the initial programs. That, of course, was the basis to initiate a collaboration around TCE. And with that, we've come to a deal that we're very happy with, one that essentially meets the objective that we set some time ago to have a first transaction in TCE and sets the stage for what we think could be a much bigger and deeper collaboration either with AbbVie or with other partners.

Carl Hansen -- Chief Executive Officer And Carl here, I'll take the second part of the question. So in September of 2023, we made a clear decision to transition from a partnership and platform model to being a clinical stage biotech. That is something that we have done successfully and that we will see come to fruition in Q2 and Q3 of this year as we get our first two CTAs submitted and ultimately get into clinical development. The rationale for simultaneously ramping down the large majority of the partnership business defined as we were running it, let's say, back in 2020, is that you need to make decisions in priority as to where you put your time and attention and your money. And we don't believe that you can walk both those roads simultaneously. So making a decision to be a clinical stage biotech means putting your focus on that objective. Now the one area where we still remain active in partnering and where I think there is some real potential to push forward the science to get interesting programs and possibly to generate significant cash that would help the business is on the TCE front. The deal with AbbVie is in line with that, and we will continue to look for such opportunities going forward.

Steve Willey -- Stifel Financial Corp. -- Analyst Understood. And then congrats on getting the AbbVie collaboration done on the TCE side. Is there a finite number of candidates that are -- that's contemplated under that collaboration? Carl Hansen -- Chief Executive Officer Great questions. First, at the highest level, we are confident in the capabilities of the TC platform that's been maturing. So we feel we're very well positioned. And we are increasingly enthusiastic based not just on internal results, but also on what's happening in the market broadly in the space of TCEs. So I think I've said it before, but the activity is clearly heating up, and that's being driven by some pretty impressive clinical results that show that you can translate some of the success from blood cancers into solid tumors. So we feel we're well-positioned for that. And the collaboration with AbbVie for us is a terrific first collaboration where we've got a meaningful TCE deal, and we're working together on multiple but a small number of targets. And with them, we're excited to explore what we think is some very promising scientific directions for TCEs that we think are gonna be important.

https://www.fool.com/earnings/call-transcripts/2025/02/27/abcellera-biologics-abcl-q4-2024-earnings-call-tra/?source=djc&utm_source=djc&utm_medium=feed&utm_campaign=article&referring_guid=f034da26-791b-4857-8beb-d36d70f8d5c7&mod=mw_quote_news

TD Cowen Keeps Their Buy Rating on AbCellera Biologics (ABCL) TipRanks Auto-Generated Intelligence Newsdesk Feb 28, 2025, 02:55 AM TD Cowen Keeps Their Buy Rating on AbCellera Biologics (ABCL) TD Cowen analyst Brendan Smith maintained a Buy rating on AbCellera Biologics (ABCL – Research Report) yesterday. The company’s shares closed yesterday at $2.92. According to TipRanks, Smith is a 3-star analyst with an average return of 4.1% and a 47.62% success rate. Smith covers the Healthcare sector, focusing on stocks such as Halozyme, Repligen, and Ginkgo Bioworks Holdings. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AbCellera Biologics with a $4.00 average price target. https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-abcellera-biologics-abcl?mod=mw_quote_news

What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earnings Feb. 26, 2025 at 7:55 a.m. ET on GuruFocus.com AbCellera Biologics Inc (ABCL, Financial) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 revenue is $7.58 million, and the earnings are expected to come in at -$0.15 per share. The full year 2024's revenue is expected to be $31.58 million, and the earnings are expected to be -$0.59 per share. More detailed estimate data can be found on the Forecast page. AbCellera Biologics Inc (ABCL, Financial) Estimates Trends Revenue estimates for AbCellera Biologics Inc (ABCL) have remained steady at $31.58 million for the full year 2024. For 2025, revenue estimates have increased from $43.13 million to $43.35 million over the past 90 days. Earnings estimates for AbCellera Biologics Inc (ABCL) have stayed constant at -$0.59 per share for the full year 2024 and at -$0.70 per share for 2025 over the past 90 days. https://www.gurufocus.com/news/2715974/what-to-expect-from-abcellera-biologics-inc-abcl-q4-2024-earnings?r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news

🔜 😎🚀💰💰💰,💰💰$

Und wann geht hier mal was ??